Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Pharmacovigilance

The legacy of general health and science information has long provided a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad context, discussions of bone health and osteoporosis management have historically emphasized the benefits of bisphosphonate therapies, such as Fosamax, in reducing fracture risk. This established knowledge base, however, has gradually expanded to include a more nuanced appreciation of potential adverse outcomes associated with long-term medication use. As the informational landscape evolved from general wellness guidance toward more specialized clinical scrutiny, attention increasingly turned to rare but serious complications linked to specific drug exposures. This shift in focus represents a natural progression from broad health education to targeted pharmacovigilance, where the same scientific rigor applied to understanding treatment efficacy is now directed at characterizing risk profiles. The transition from a general health perspective to a focused examination of Fosamax exposure and its potential association with osteonecrosis of the jaw reflects this maturation of clinical inquiry.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with pain, swelling, and infection. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The diagnosis is primarily clinical, based on the presence of exposed bone in the jaw that persists for more than eight weeks in the absence of prior radiation therapy. Multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique structural and cellular properties of the jawbone that may predispose it to ONJ under certain conditions.

Fosamax Pharmacology and Reported Adverse Effects

Fosamax (alendronate sodium) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing fracture risk. Its pharmacology involves binding to hydroxyapatite in bone and being released during bone remodeling, where it is taken up by osteoclasts and induces apoptosis. The drug is indicated for osteoporosis in postmenopausal women, men with osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, adverse effects include gastrointestinal symptoms, musculoskeletal pain, and, notably, ONJ. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, but ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms varied from one day to several months after starting the drug, and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The exact mechanism by which bisphosphonates like Fosamax contribute to ONJ is not fully understood, but several pathways have been proposed. Bisphosphonates suppress bone turnover by inhibiting osteoclast activity, which may impair the normal repair and remodeling of jawbone after dental procedures or microtrauma. This suppression can lead to accumulation of microdamage and reduced blood supply, predisposing the bone to necrosis. Additionally, bisphosphonates may have anti-angiogenic effects, further compromising vascularity. The jawbone's high rate of remodeling and its exposure to oral microbiota may make it particularly vulnerable. Multiscale characterization of jawbone has provided insights into these jawbone-specific responses, helping to elucidate why ONJ occurs preferentially in the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Risk Anchors: Adequacy of Warnings and Causation Considerations

The prescribing information for Fosamax includes a warning about ONJ, stating that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning notes that ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the adequacy of these warnings has been questioned, particularly regarding the timing of onset and the need for dental evaluation before initiating therapy. The time to onset of symptoms varied from one day to several months after starting the drug, and a subset of patients had recurrence of symptoms when rechallenged (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates risk assessment for individual patients. For affected patients, causation considerations include the temporal relationship between Fosamax exposure and ONJ development, the presence of other risk factors, and the biological plausibility of the link. The timeline between exposure and documented harm can range from days to months, and the risk may increase with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients with multiple risk factors, such as those undergoing dental procedures or receiving concomitant corticosteroids, may be at higher risk. The recurrence of symptoms upon rechallenge with the same or another bisphosphonate supports a causal relationship (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinicians should weigh the benefits of Fosamax in preventing fractures against the risk of ONJ, especially in patients with low fracture risk, for whom drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the jaw, often with pain, swelling, and infection. It is diagnosed clinically when exposed bone persists for more than eight weeks without prior radiation therapy. ONJ has been reported in patients taking bisphosphonates like Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

The exact mechanism is not fully understood, but Fosamax suppresses bone turnover by inhibiting osteoclast activity, which may impair jawbone repair after dental procedures or microtrauma. This can lead to microdamage accumulation and reduced blood supply, predisposing to necrosis. Anti-angiogenic effects may also contribute. The jawbone's high remodeling rate and oral microbiota exposure make it particularly vulnerable (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). Risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ occur?

The time to onset of ONJ symptoms can vary from one day to several months after starting the drug. Most patients experience relief after stopping, but a subset may have recurrence upon rechallenge with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.